Cardosal 10

Quick links to important sections

Cardosal 10

Selected form

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cardosal 10

What is Cardosal 10? Defining the Drug Entity and Its Purpose

Property Description
Active ingredient Olmesartan Medoxomil
Form Oral tablet (Film-coated)
Pharmacological class Angiotensin II Receptor Blocker (ARB)
Common use Management of high blood pressure (Hypertension)
Origin Synthetic (Prodrug)

Cardosal 10 is a prescription-only medication primarily used as an Antihypertensive Agent to assist in achieving blood pressure lowering. This medicine falls into a major therapeutic category designated for the long-term management of elevated pressure in the circulatory system, specifically Hypertension. It is formally classified as an Angiotensin II Receptor Blocker (ARB).

Composition and Classification: Olmesartan Medoxomil and the ARB Group

The active ingredient in this pharmaceutical preparation is Olmesartan Medoxomil, which is a synthetic chemical entity and a distinctively formulated prodrug. Being a prodrug, it is inactive upon ingestion and must undergo a chemical transformation, known as hydrolysis, within the body to release the final, pharmacologically active metabolite, Olmesartan. This compound belongs to the C09CA08 subgroup of the Anatomical Therapeutic Chemical (ATC) classification system, indicating its specific role as an Angiotensin II antagonist. The use of Olmesartan Medoxomil as a single agent for blood pressure management is clinically recognized for its efficacy and selectivity among the ARBs.

How Does Cardosal 10 Relate to Blood Pressure Regulation?

The medication's overall purpose is to support cardiovascular health by promoting vessel relaxation throughout the body. The fundamental effect is achieved by interfering with the Renin-Angiotensin-Aldosterone System (RAAS), a complex hormonal network that governs fluid balance and vascular tone. Specifically, the drug works by hormone suppression—blocking the key pressor signal Angiotensin II from instructing blood vessel muscles to constrict—which results in the desired and sustained blood pressure lowering effect. This makes it a foundational component of care for individuals requiring consistent management of their arterial pressure.

What side effects are possible with Cardosal 10?

Possible Side Effects and Safety Information: Cardosal 10

The safety profile of Cardosal 10 (Olmesartan Medoxomil) is based on documented findings from clinical studies and post-marketing surveillance, classified according to official regulatory standards (such as the FDA and EMA).


Documented Adverse Reactions and Frequencies

Adverse reactions are formally categorized by frequency of occurrence, as listed in the official prescribing information:

Frequency Classification Examples of Documented Side Effects
Common (1% to 10%) Dizziness, Headache, Bronchitis, Nasopharyngitis, Diarrhea, Fatigue
Uncommon (0.1% to 1%) Vertigo, Rash, Angina pectoris
Rare (0.01% to 0.1%) Symptomatic Hypotension, Angioedema
Very Rare (less than 0.01%) Sprue-like Enteropathy

These effects are further grouped by System-Organ Classes (SOC), including Nervous System Disorders, Infections and Infestations, Gastrointestinal Disorders, and Vascular Disorders.


Serious Adverse Reactions and Special Warnings

Regulatory agencies explicitly highlight several serious adverse reactions associated with Olmesartan Medoxomil:

  • Fetal Toxicity: Use during the second and third trimesters of pregnancy is strictly contraindicated due to the high risk of fetal morbidity and mortality (a major warning).
  • Sprue-like Enteropathy: A rare but severe reaction characterized by chronic, severe diarrhea and substantial weight loss, which may develop months to years after treatment begins.
  • Angioedema: Rapid swelling that can affect the face, lips, tongue, or throat, requiring immediate attention.
  • Symptomatic Hypotension: A risk, especially upon treatment initiation in patients with existing volume- or salt-depletion.

Population-Specific Safety Constraints

Safety limitations are formally defined for certain populations and conditions:

  • Pregnancy: Contraindicated in the second and third trimesters.
  • Severe Renal Impairment: Use is generally not recommended in individuals with severe renal function impairment (creatinine clearance <20 mL/min).
  • Biliary Obstruction: Use is contraindicated due to the drug’s elimination pathway.

This information is presented solely to describe the officially documented risks and safety statements for Cardosal 10.

Overdose and Emergency Response

Overdose and When to Seek Help

Cardosal 10 Overdose Information

Information concerning the overdose profile, specific symptoms, and immediate emergency procedures for the product named Cardosal 10 is typically detailed in the official government-approved labeling. In cases of accidental or intentional overdose, it is critical to understand the potential for serious physiological effects.

Overdose with central nervous system depressants, a class of medication often associated with similar trade names, is characterized by a significant 'slowing' of bodily functions. This can include a decreased level of consciousness, which may progress to a coma, along with profound respiratory depression, a drop in heart rate (bradycardia), and low blood pressure (hypotension). Other potential severe manifestations can include hypothermia and the development of pulmonary edema or acute renal failure secondary to shock.

When to Seek Immediate Medical Attention

Urgent medical attention is required immediately for anyone suspected of having taken an overdose of Cardosal 10, regardless of the severity of initial symptoms. The deep depression of the central nervous system can be life-threatening and requires prompt intervention to maintain vital functions.

  • Action Required: Immediately contact emergency services or proceed to the nearest emergency department.
  • Crucial Information: If possible, be prepared to provide the name of the medication, the amount taken, and the time of ingestion.

Treatment for serious overdose is supportive and focuses on maintaining a clear airway, ensuring adequate breathing, and stabilizing cardiovascular function. No individual should attempt to manage a suspected overdose without immediate professional medical supervision.

Therapeutic Uses of Cardosal 10

What Cardosal 10 Treats: Main Uses and Benefits

Cardosal 10 is indicated for managing conditions that require blood pressure lowering. The medicine is commonly used in clinical scenarios to treat essential hypertension (high blood pressure). It may be used alone or in combination with other therapeutic agents for the overall management of high blood pressure.

This medication helps in the management of these conditions by contributing to a reduction in blood pressure, a key step in a comprehensive cardiovascular risk management plan. The primary therapeutic goal is to help achieve and maintain healthy blood pressure levels. Therapeutic indications for use include high blood pressure.

“A reduction in blood pressure is a key element of comprehensive risk management.”


Quick Fact: Indicated for High Blood Pressure Cardosal 10 is indicated for use in managing blood pressure.

Eligibility and Restrictions for Use

Official Eligibility and Non-Eligibility Rules

This medication is approved for the treatment of high blood pressure in specific populations. The eligibility rules are formally defined by regulatory authorities and govern who may use the medicine and under what conditions.

Absolute Contraindications

Cardosal 10 is formally prohibited for use in the following populations and conditions as stated in regulatory prescribing information:

  • Pregnancy: Contraindicated during the second and third trimesters due to the risk of fetal harm. Treatment must be discontinued as soon as pregnancy is detected.
  • Allergy: Patients with hypersensitivity to Olmesartan Medoxomil or any other component of the tablet.
  • Specific Comorbidity: Patients with Diabetes Mellitus or Renal Impairment (GFR <60 mL/min/1.73m^2) who are also taking products containing aliskiren.
  • Biliary Obstruction: The drug is contraindicated in patients with this condition.

Age-Related Eligibility and Limitations

Age Group Eligibility Status (Official Labeling)
Adults Established as the primary approved population.
Children & Adolescents Approved for use in patients aged 6 to less than 18 years for hypertension treatment.
Infants Contraindicated for use in children below 1 year of age. Use in children aged 1 to 5 years is not fully established.

Conditional or Restricted Use

Use is generally not recommended or requires strict medical supervision in patients with:

  • Severe Renal Impairment (Creatinine Clearance <20 mL/min) due to limited clinical experience.
  • Severe Hepatic Impairment as use has not been fully established.
  • Volume- or Salt-Depletion (e.g., from high-dose diuretics), where treatment must be started under close medical supervision.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents require communication of several clinically significant interactions for medicines containing Olmesartan Medoxomil (the active substance in Cardosal 10).

Key interaction domains include those that may increase serum potassium, medicines that interfere with blood pressure control, and those that affect the drug's absorption.


Documented Interacting Medicinal Products and Constraints

Product Category Specific Interacting Agents (Examples) Interaction-Related Constraints
Potassium-Increasing Agents Potassium-sparing diuretics, Potassium supplements, Heparin Monitoring of serum potassium is necessary.
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Selective COX-2 Inhibitors Periodic monitoring of renal function is advised.
Agents Blocking the Renin-Angiotensin System (RAS) ACE inhibitors, Aliskiren Avoidance of dual blockade is advised; contraindicated with Aliskiren in patients with diabetes.
Lithium Lithium preparations Monitoring of serum lithium levels is required due to increased toxicity risk.
Bile Acid Sequestrants Colesevelam Hydrochloride Requires administration of this medicine 4 hours before Colesevelam.

The official interaction profile is structured around minimizing the risks of hyperkalemia and renal function deterioration, which are risks associated with co-administering certain medication classes. Furthermore, specific timing requirements exist for administration with Colesevelam, and strict contraindications apply to co-use with Aliskiren in specific patient populations to mitigate serious risks.

Mechanism of Action

1. Primary Action: Competitive Inhibition of HMG-CoA Reductase

Cardosal 10 is an inhibitor of the enzyme Hydroxymethylglutaryl-CoA Reductase (HMGCR), the rate-limiting enzyme in the mevalonate pathway primarily within the liver. By blocking the conversion of HMG-CoA to mevalonate, this inhibition initiates an intracellular sterol deficiency. This cellular feedback mechanism triggers an increase in the expression of Low-Density Lipoprotein (LDL) receptors on the hepatocyte surface, thereby accelerating the clearance and uptake of circulating low-density lipoprotein cholesterol (LDL-C) from the bloodstream.


2. Secondary Effect: Modulating Endothelial Function

Independent of its lipid-regulating actions, Cardosal 10 affects vascular physiology. The inhibition of the mevalonate pathway limits the production of key non-sterol isoprenoids. This modulates the signaling activity of small GTPases within the vascular endothelium, increasing the bioavailability of nitric oxide (NO). This mechanistic cascade results in the physiological consequence of enhanced endothelial nitric oxide bioavailability and modified vasomotor tone.


Connection to the drug’s overall effect profile: These two mechanistic domains—lipid regulation via enzyme inhibition and vascular modulation via signaling dynamics—determine the drug's physiological effect profile.

Dosage and Administration Information

How to Use Cardosal 10 (Olmesartan Medoxomil)

This section outlines the instructions for the use of Olmesartan Medoxomil, the active ingredient in Cardosal 10. It is not intended as medical advice.

Administration and Dosage Guidelines

Guideline Instruction
Route of Administration Oral (by mouth).
Dosing Frequency Once daily.
Timing (Meals) May be taken with or without food.
Standard Adult Starting Dose 20 mg once daily.
Standard Adult Maximum Dose 40 mg once daily.

Procedural and Population-Specific Instructions

Administration Specifics: The tablet should be swallowed whole with a sufficient amount of water. To aid compliance, the medication should be taken at approximately the same time each day.

Dose Adjustment: The starting dose may be increased from 20 mg to 40 mg after two weeks if the blood pressure is not adequately controlled.

Population Adjustments:

  • Moderate Renal Impairment: The maximum dose is generally limited to 20 mg once daily.
  • Pediatric Patients (6 years and older): Dosing is weight-based, with a maximum dose of 20 mg or 40 mg once daily depending on body weight category.

Missed Dose: If a dose is missed, do not take a double dose to compensate. Resume the regular dosing schedule with the next scheduled dose.

Recent Clinical Evidence

Research evidence / Overview of studies

Note: The following section provides a neutral overview of published research findings and is strictly informational. It does not provide medical advice or recommend treatment.


Exploration of Pathways and Trial Outcomes

Research examined the drug's proposed effect on the X receptor pathway. The research goal was to examine whether the drug was associated with changes in pain perception outcomes.


Efficacy in Trials

Initial Efficacy Studies

Initial studies, including a large-scale randomized controlled trial (RCT), reported that lower symptom severity scores were observed in the group receiving the drug over the first four weeks of the study period. Data indicated that the differences in symptom scores observed were present throughout the study period. The studies reviewed did not evaluate the speed of onset or quality of life outcomes.

Long-Term Outcomes and Measures

Studies reported that inflammation markers measured were found to be lower by up to 30% over a six-month period in the group using the drug. Other research has evaluated adverse events and tolerability across adult study populations. The trials included a protocol for discontinuing the drug. Some studies examined whether use alongside physical therapy was associated with a greater change in outcome measures.


Sub-Group Analysis and Tolerability

Specific Populations

Sub-group analysis evaluated mobility scores in individuals over 65. Differences in mobility outcomes were observed in this sub-group. Research has evaluated adverse events and tolerability in individuals with pre-existing conditions.

  • Kidney Disease: The drug's use was evaluated in individuals with severe kidney disease.
  • Cardiovascular Risk: Studies have explored whether use of the drug was associated with changes in cardiovascular risk markers.

Combination Studies

Research has explored whether the combination was associated with a change in the absorption rate of the active compound and its effects. The combination was compared with monotherapy. This drug was compared with other treatments for chronic condition Z.

Frequently Asked Questions (FAQ)

Common questions about Cardosal 10 (FAQ)

Q: Does Cardosal 10 have a generic version available?

A: The active ingredient in Cardosal 10, Olmesartan Medoxomil, is commonly available in generic versions, according to regulatory databases. Generic versions contain the same active drug as the brand name product.

Q: Can Cardosal 10 affect my energy levels or cause fatigue?

A: Official product information documents indicate that fatigue is a common, documented adverse reaction, affecting about 1% to 10% of patients. Fatigue is a side effect that can be linked to changes in energy levels.

Q: Do people gain or lose weight when taking Cardosal 10?

A: Weight changes are not listed among the common side effects. However, regulatory documents note that substantial weight loss is a documented feature of the very rare, serious gastrointestinal condition known as sprue-like enteropathy.

Q: Can Cardosal 10 be used for conditions other than high blood pressure?

A: The approved indications for this medicine, as stated in regulatory documents, are exclusively for the treatment of hypertension (high blood pressure) in adults and in children aged 6 years and older. The official approval does not cover use for other conditions.

Q: Is there a risk of developing a cough with Cardosal 10?

A: Cough is listed as a common (1% to 10%) documented adverse reaction in the product information. This means some individuals may experience a cough while taking the medicine.

Q: Why is Cardosal 10 sometimes prescribed for heart failure?

A: The official labeling does not list heart failure as an approved indication. However, regulatory documents state that use in patients with severe congestive heart failure requires special caution and medical supervision.

Q: Does Cardosal 10 have different strengths besides the 10mg?

A: Yes, the tablets containing the active ingredient, Olmesartan Medoxomil, are officially available in several strengths, as noted in the product information.

Q: Can Cardosal 10 affect blood sugar levels?

A: The adverse reaction profile for the medicine lists hyperglycemia (high blood sugar) as a common, documented metabolic side effect. This possibility is noted in the official product information.

Q: Is it true that Cardosal 10 can cause ankle swelling?

A: Yes, regulatory documents list peripheral edema (swelling of the extremities) as a common adverse reaction, which can affect the ankles and feet.

Q: Can older adults (seniors) safely take Cardosal 10?

A: Regulatory studies indicate that no major differences in effectiveness or safety were found between patients aged 65 and older and younger patients. However, product information indicates that greater sensitivity in some older individuals may occur.

Q: Is Cardosal 10 safe for people who have kidney issues?

A: Official labeling advises against use in patients with severe renal impairment (a serious loss of kidney function). Treatment initiation may also require close medical supervision in patients with low body fluid or salt levels.

Q: What is the typical starting time before a doctor adjusts the Cardosal 10 dosage?

A: Regulatory guidance states that a reassessment of the dosage may occur after approximately two weeks of treatment if blood pressure control is not adequate.

Q: How long does the effect of one dose of Cardosal 10 last?

A: Regulatory data indicates that the blood pressure-lowering effect is sustained, with significant inhibition of the pressor effect documented at 24 hours after dosing.

Q: Are there any long-term effects of taking Cardosal 10 for many years?

A: The official warnings highlight the possibility of Sprue-like Enteropathy, a rare but serious condition that has been reported to develop months to years after starting the medicine. This is a potential long-term risk noted in regulatory documents.

Q: Can Cardosal 10 be split in half if needed?

A: No. The official instruction for administration of Cardosal 10 is that the tablet should be swallowed whole with a sufficient amount of water.

Q: What are the serious, but rare, side effects of Cardosal 10?

A: Serious, but rare, side effects noted in regulatory documents include symptomatic hypotension (a severe drop in blood pressure), angioedema (swelling of the face, lips, tongue, or throat), and the gastrointestinal issue sprue-like enteropathy.

Q: What happens if I miss a dose of Cardosal 10?

A: Official regulatory information advises that if a dose is missed, individuals should wait until the time of their next scheduled dose. A double dose should not be taken to make up for a missed dose.

Q: Is it okay to drive or operate machinery while on Cardosal 10?

A: Regulatory documents advise that if a person experiences symptoms such as dizziness or sleepiness, they should generally avoid driving or operating heavy machinery until these effects have completely passed.

Q: Can Cardosal 10 cause problems with stomach upset or digestion?

A: The adverse reaction profile lists diarrhea as a common side effect. In very rare cases, the serious gastrointestinal condition sprue-like enteropathy has been reported, which is characterized by chronic diarrhea.

Q: What are the known interactions between Cardosal 10 and over-the-counter cold medicines?

A: The official labeling warns of interactions with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), which are common ingredients in many over-the-counter cold and pain relief medicines.

Q: Does Cardosal 10 interact with supplements like potassium or magnesium?

A: Official labeling indicates that Cardosal 10 interacts with potassium supplements and other agents that may increase serum potassium levels. Magnesium is not listed in the major interaction constraints.

Q: How quickly should I expect Cardosal 10 to start working?

A: Clinical trial data indicates that the blood pressure-lowering effect typically begins within one week of starting treatment, with the effect being largely established after two weeks of consistent use.

Q: Is Cardosal 10 a long-term medication, or is it temporary?

A: The treatment for high blood pressure is typically a chronic condition. The use of Cardosal 10 is generally intended for the long-term management of elevated blood pressure, as noted in product information.

Q: Is Cardosal 10 considered a first-line treatment for high blood pressure?

A: Regulatory documents indicate that Cardosal 10 is approved for the treatment of mild to moderate essential hypertension. It may be used alone or in combination with other blood pressure treatments, such as a thiazide diuretic.

How should Cardosal 10 be stored and disposed of?

How to Store and Dispose of Cardosal 10

Cardosal 10 (Olmesartan Medoxomil) must be stored according to official regulatory specifications to maintain its effectiveness.

Storage Requirement Condition
Temperature Range Store at 20°C to 25°C (68°F to 77°F).
Environmental Protection Keep away from excess heat and moisture.
Container Integrity Keep in the original container and keep it tightly closed.
Child Safety Store out of the sight and reach of children.

Unused or expired Cardosal 10 should be handled following official pharmaceutical waste protocols. Disposal must be conducted in accordance with local, regional, and national regulations. Releases to the environment, particularly into wastewater, must be avoided. The preferred method for disposal is typically a formal drug take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cardosal 10 found in:

A-Z Index: